Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cx43-M2
- Development stage
- Unknown
- Lead developer
- AlaMab Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
Cx43-M2 (also known as ALMB-0168 in its humanized form) is a first-in-class monoclonal antibody agonist that specifically targets and activates connexin 43 (Cx43) hemichannels in osteocytes. Developed by researchers at the University of Texas Health Science Center at San Antonio and licensed to AlaMab Therapeutics (a subsidiary of CSPC Pharmaceutical Group), Cx43-M2 binds to the second extracellular loop of Cx43, promoting hemichannel opening and the subsequent release of adenosine triphosphate (ATP) and prostaglandin E2 (PGE2) into the extracellular microenvironment. This action suppresses tumor growth and metastasis in bone-involved cancers, such as osteosarcoma and breast cancer bone metastasis, by transforming the bone microenvironment from tumor-supportive to tumor-suppressive and enhancing anti-tumor immunity (e.g., activating CD8+ cytotoxic T cells). Additionally, Cx43-M2-mediated hemichannel activation has shown therapeutic potential in preventing bone loss and osteocyte apoptosis associated with disuse (mechanical unloading) and aging.
- Other names
- humanized Cx43-M2M2(H)M2(MH)
02
Targets
GJA1 (Connexin43 Hemichannel)
Beyond the preview
Go deeper on Cx43-M2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cx43-M2.